VRTX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 19.72%. Vertex Pharmaceuticals's return on equity of -6.04% beat Gilead Sciences's return on equity of 32.29%.

Vertex Pharmaceuticals has a consensus price target of $500.30, signalling upside risk potential of 6.55%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

Vertex Pharmaceuticals has a beta of 0.410, which suggesting that the stock is 59.044% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Vertex Pharmaceuticals's net income of $646.3M is lower than Gilead Sciences's net income of $1.3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.96x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 21.68%. Vertex Pharmaceuticals's return on equity of -6.04% beat Eli Lilly and's return on equity of 78.25%.

Vertex Pharmaceuticals has a consensus price target of $500.30, signalling upside risk potential of 6.55%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.410, which suggesting that the stock is 59.044% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Vertex Pharmaceuticals's net income of $646.3M is lower than Eli Lilly and's net income of $2.8B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.96x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 32.71%. Vertex Pharmaceuticals's return on equity of -6.04% beat Merck &'s return on equity of 39.02%.

Vertex Pharmaceuticals has a consensus price target of $500.30, signalling upside risk potential of 6.55%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Vertex Pharmaceuticals, analysts believe Merck & is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.410, which suggesting that the stock is 59.044% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Merck & quarterly revenues of $15.5B. Vertex Pharmaceuticals's net income of $646.3M is lower than Merck &'s net income of $5.1B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.96x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 21.63%. Vertex Pharmaceuticals's return on equity of -6.04% beat Pfizer's return on equity of 8.72%.

Vertex Pharmaceuticals has a consensus price target of $500.30, signalling upside risk potential of 6.55%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Pfizer has higher upside potential than Vertex Pharmaceuticals, analysts believe Pfizer is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.410, which suggesting that the stock is 59.044% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Pfizer quarterly revenues of $13.7B. Vertex Pharmaceuticals's net income of $646.3M is lower than Pfizer's net income of $3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.96x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.